A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis
ConditionRheumatoid Arthritis
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorXencor, Inc.
About this trial
The purpose of this study is to determine the safety and tolerability of plamotamab in patients with rheumatoid arthritis. Participants will be given XmAb13676 subcutaneously (SC) by injection under the skin.
Eligibility criteria
Qualifiers
Documented diagnosis of RA and meeting the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for RA at least 3 months prior to screening
Inadequate response to, loss of response to, or intolerance to available RA therapies.
Stable doses of RA medications prior to screening
Use of highly effective methods of contraception
Disqualifiers
Major surgery within 12 weeks prior to screening or planned within 12 months after dosing
Recurrent infections or active clinically significant infection
Active or untreated latent tuberculosis
Cancer or history of cancer or lymphoproliferative disease within the previous 5 years
Trial design
Treatments tested in this trial
- Plamotamab
Treatment groups
68 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov